MedCity News

FEBRUARY 1, 2024

The more pharma companies do to become service providers in the personalized medicine era, the more they’ll succeed and the more lives they’ll help to save.

Medicine 264

Medicine Pharma Healthcare Healthcare 264

MedCity News

SEPTEMBER 30, 2024

Bristol Myers Squibb is turning to the prime-editing technology of Prime Medicines for the R&D of new cell therapies for cancer and immunology. The pharma giant is paying $110 million up front to begin the collaboration.

Medicine 289

Medicine Pharma Biopharma 289

MedCity News

OCTOBER 2, 2024

Lilly Medicine Foundry will research new ways to manufacture medicines. Medicine Foundry to Foster Innovations in Drug Manufacturing appeared first on MedCity News. The post Eli Lilly Plans $4.5B

Manufacturing 305

Manufacturing Medicine Biopharma Pharma 305

Contrarian Sales Techniques

NOVEMBER 19, 2024

It’s a reality for many of us in pharma sales in Malaysia. Counterfeit medicines aren’t just a risk to patients’ health – they’re a blow to the industry’s reputation and our efforts to promote genuine, high-quality treatments. What Are Counterfeit Medicines? Counterfeit medicines, on the other hand, are illegal.

Medicine 52

Medicine Sales Pharma Doctors 52

MedCity News

NOVEMBER 14, 2024

Merck is acquiring global rights to a bispecific antibody from LaNova Medicines that blocks two cancer targets, PD-1 and VEGF. The deal comes one day after BioNTech announced an $800 million acquisition that gives it full rights to a molecule in this hot class of cancer drug candidates.

Medicine 306

Medicine Biopharma Pharma 306

MedCity News

SEPTEMBER 27, 2022

Prime Medicine likens its gene-editing technology to a word processor that searches for the correct place in the genome to make an edit, replacing or repairing a wide variety of target DNA. The preclinical biotech is now spelling out its future plans with the letters I-P-O.

Medicine 325

Medicine Biopharma Pharma 325

MedCity News

APRIL 25, 2024

The post Regeneron Bets $100M That Mammoth’s CRISPR Tech Can Deliver on Next Wave of Genetic Medicines appeared first on MedCity News. The deal marks the third pharmaceutical industry partnership for Mammoth, which initially focused on developing CRISPR-based diagnostics.

Medicine 336

Medicine Pharmaceutical Biopharma Pharma 336

MedCity News

NOVEMBER 10, 2024

By fostering collaboration and seamless data integration into healthcare systems, the industry is laying the groundwork for a future in which “personalized medicine” is so commonplace within clinical practice that we will just start calling it “medicine.”

Patients 311

Patients Medicine Healthcare Healthcare 311

MedCity News

JANUARY 10, 2025

Ouro Medicines drugs deplete disease-driving immune cells, allowing the immune system to reset with nave cells that dont attack the body. Monograph Capital founded the startup in partnership with GSK. The post Immunology Startup Ouro Sets Out With $120M for Drugs That Reset the Immune System appeared first on MedCity News.

Medicine 262

Medicine Biopharma Pharma 262

MedCity News

OCTOBER 22, 2024

Editas Medicine says its in vivo gene-editing therapy for hemoglobinopathies has best-in-class potential, but the company plans to out-license or partner that program. The post Editas Medicine Seeks Partner for Ex Vivo Gene-Editing Program as Focus Turns to In Vivo R&D appeared first on MedCity News.

Medicine 289

Medicine Biopharma Pharma 289

MedCity News

NOVEMBER 8, 2024

Use of this ingredient in cold and allergy medicines grew after a federal law required that pseudoephedrine-containing products be kept behind pharmacy counters. The FDA has proposed removing oral phenylephrine from its guidelines for over-the-counter drugs due to inefficacy as a decongestant.

FDA 306

FDA Marketing Medicine Biopharma 306

MedCity News

DECEMBER 22, 2024

The new approval gives the Eli Lilly medicine the opportunity to become a blockbuster seller in yet another indication. Zepbounds clinical tests in obstructive sleep apnea showed improvement in breathing disruptions that were accompanied by reductions in body weight.

FDA 287

FDA Medicine Biopharma Pharma 287

Fierce Pharma

DECEMBER 12, 2023

Tuesday, the European Medicines Agency laid out a list of more than 300 critical generic drugs that could fall prey to future shortages. Over the past several years, drug shortages have vexed doctors and patients on both sides of the Atlantic, prompting lawmakers and government agencies to take action in both Europe and the U.S.

Medicine 331

Medicine Doctors Government Patients 331

MedCity News

FEBRUARY 29, 2024

Orbis Medicines is developing macrocyclic peptides that address a wider range of targets and can be taken as oral pills. Novo Holdings and Forbion are backing the startup, which is based on research from the scientific co-founder of peptide drug developer Bicycle Therapeutics.

Medicine 289

Medicine Biopharma Pharma 289

MedCity News

FEBRUARY 2, 2025

Investors showed appetite for Metseras IPO, as shares of the clinical-stage metabolic medicines biotech popped 47% in their Nasdaq debut. Maze Therapeutics and Beta Bionics also priced IPOs; the three companies raised $636 million combined.

Medicine 297

Medicine Biopharma Pharma 297

MedCity News

JANUARY 8, 2025

Metabolic medicines dominated life sciences headlines in 2024, a trend expected to continue into the new year. Other things to look for include more widespread adoption of artificial intelligence technologies and the IPO markets return to normal levels.

Biopharma 311

Biopharma Medicine Marketing FDA 311

Fierce Pharma

DECEMBER 17, 2024

| After the recent release of two independent studies from the University of Southern Denmark suggested the use of Ozempic increases patients' chances of developing a rare eye disorder, the Danish Medicines Agency has asked European officials to investigate.

Medicine 272

Medicine Patients 272

Fierce Pharma

OCTOBER 22, 2024

Telix on Tuesday unveiled the spin-off of Rhine Pharma—a new entity born from a collaboration between Telix and Germany’s Heidelberg University Hospital—which is setting out on a mission to expand access to radiopharmaceuticals for cancer treatment and imaging. There’s no denying it: the radiopharmaceuticals boom is here to stay.

Pharma 202

Pharma Medicine 202

Fierce Pharma

OCTOBER 31, 2024

25 mg presentation of the popular metabolic medicine was the last dose of either Wegovy or its type 2 diabetes sibling Ozempic to be listed as in shortage by the FDA. 25 mg starter dose of Novo’s semaglutide-based obesity med Wegovy is now available in the U.S.

FDA 281

FDA Medicine 281

Fierce Pharma

NOVEMBER 1, 2024

With a positive readout for metabolic dysfunction-associated steatohepatitis (MASH) now in the bag, Novo Nordisk is gearing up to pursue yet another indication for its star GLP-1 medicine semagluti | Novo Nordisk on Friday revealed that its star GLP-1 semaglutide met the mark in a late-stage MASH study.

Medicine 320

Medicine 320

MedCity News

OCTOBER 20, 2022

Prime Medicine has yet to test prime editing in humans, but the biotech company garnered enough investor interest to boost the size of its IPO, raising $175 million. Prime claims its technology has key advantages over other gene-editing technologies and the IPO cash will support a pipeline that currently spans 18 programs.

Medicine 278

Medicine Biopharma Pharma 278

Fierce Pharma

FEBRUARY 22, 2024

As Roche officially abandoned cancer drug Gavreto, its former partner Blueprint Medicines has found the RET inhibitor a new owner in the U.S. | As Roche officially abandoned cancer drug Gavreto, its former partner Blueprint Medicines has found the RET inhibitor a new U.S. owner in Rigel Pharmaceuticals.

Medicine 263

Medicine Pharmaceutical 263

MedCity News

NOVEMBER 24, 2024

Halozyme views its drug delivery technology for biologic medicines as complementary to Evotec’s biologic drug manufacturing capabilities. But according to Halozyme, Evotec was unwilling to engage in any merger discussions. The post Halozyme Pulls €2B Acquisition Bid as Evotec Commits to Standalone Strategy appeared first on MedCity News.

Manufacturing 276

Manufacturing Medicine Biopharma Pharma 276

MedCity News

NOVEMBER 20, 2024

We cannot change the fact that some patients must take multiple drugs, but we can certainly change how we manage it with careful coordination and communication among healthcare providers, and personalized medicine practices such as pharmacogenomics.

Management 297

Management Medical Healthcare Provider Medicine 297

MedCity News

AUGUST 16, 2022

Biotech startup Senda Biosciences is developing technology that yields a new type of medicine with two programming components: one directs the therapy to go to a particular destination in the body while the second tells the therapy what to do once it gets there. With the Series C financing, Senda aims to reach the clinic in 2024.

Medicine 245

Medicine Biopharma Pharma 245

Fierce Pharma

MAY 28, 2024

A data breach at drug distributor Cencora has left sensitive information vulnerable, with patients on medicines from a dozen drugmakers potentially affected. | The potentially compromised data included patient information such as names and addresses, Cencora disclosed in letters to patients who may have been affected.

Patients 280

Patients Pharma Medicine 280

Fierce Pharma

NOVEMBER 20, 2024

Roche's spinal muscular atrophy (SMA) medicine Evrysdi only gained its FDA approval in 2020, but generics companies are already eying the blockbuster as a potential target. | The spinal muscular atrophy drug is a growth driver for the Swiss pharma giant, prompting the company to prioritize its defense against potential generics.

Medicine 309

Medicine FDA Pharma 309

Fierce Pharma

DECEMBER 2, 2024

The FDA notification came seven weeks after the New England Journal of Medicine (NEJM) published a report that seven of 67 children who received Skysona during clinical trials had developed blood cancer. agency said last week.

FDA 250

FDA Medicine Patients 250

Fierce Pharma

OCTOBER 25, 2024

The FDA nod marks the second approval this year for a uUTI medicine after two decades of stagnation in the field. . | Iterum's Orlynvah was approved by the FDA Friday to treat certain uncomplicated urinary tract infections (uUTIs) in adult women who have limited or no alternative antibacterial treatment options.

FDA 225

FDA Medicine 225

MedCity News

OCTOBER 26, 2023

Digital therapeutics have shown how therapy can be delivered effectively through a digital interface, but the bankruptcy of Pear Therapeutics raised questions about whether these technologies can be commercially successful.

Medicine 287

Medicine Biopharma Pharma 287

World of DTC Marketing

JUNE 20, 2022

Pharma DTC marketing is unique, and drug marketers need to think more about the journey from awareness to requesting an Rx. The hottest pharma product is Lilly’s diabetes drug, hyped by the media as helping patients lose weight. The post Uniqueness if pharma DTC. appeared first on World of DTC Marketing.com.

Pharma 210

Pharma Side effects Media Marketing 210

Fierce Pharma

NOVEMBER 15, 2024

In a flurry of activity, Europe’s human medicines committee has done an about-face on Eisai and Biogen’s Alzheimer’s disease med Leqembi, endorsed a clutch of biosimilars, recommended a slew of lab | In a flurry of activity, the European Medicines Agency's CHMP has done an about-face on Eisai and Biogen’s Alzheimer’s disease med Leqembi, endorsed (..)

Medicine 205

Medicine 205

MedCity News

APRIL 17, 2023

Merck is acquiring Prometheus Biosciences and a lead drug candidate in development for inflammatory bowel disorders. The deal comes as Merck looks for drug prospects that could make up for revenue declines facing blockbuster seller Keytruda, which faces patent expirations in coming years.

Medicine 292

Medicine Prospecting Leads Biopharma 292

MedCity News

JANUARY 28, 2024

While pharmaceutical companies continue to raise list prices year-over-year, we work behind the scenes to fight the trend by driving competition, negotiating with drugmakers and incentivizing the use of less expensive medicines that deliver the same clinical value.

Competition 325

Competition Medicine Pharma Patients 325

Fierce Pharma

FEBRUARY 16, 2024

A Novartis subsidiary in India has become the target of a strategic review as the Swiss pharma focuses its efforts on newer medicines. | A Novartis subsidiary handling old products in India has become the target of a strategic review as the Swiss pharma focuses its efforts on newer medicines.

Medicine 249

Medicine Pharma 249

Fierce Pharma

AUGUST 30, 2024

ESC 2024: UK's George Medicines posts positive results for triple-combo blood pressure drug on heels of FDA submission fkansteiner Fri, 08/30/2024 - 15:54

Medicine 210

Medicine FDA 210

Pharma Marketing Network

NOVEMBER 23, 2024

From AI-powered insights to the rise of precision medicine, new trends are reshaping the way we connect with patients and healthcare providers. The Connection Between Pharma Research and Marketing Effective marketing starts with understanding your audience.

Marketing 52

Marketing Pharma Ethics Healthcare Provider 52